InVivoMAb大鼠IgG2b同種型對照，孔血藍蛋白研究專用

LTF-2單克隆抗體與鑰匙孔血藍蛋白（KLH）反應。由于哺乳動物不表達KLH，這種抗體非常適合在大多數體內和體外應用中用作大鼠IgG2b抗體的同種型匹配對照。

艾美捷InVivoMAb大鼠IgG2b同種型對照，抗鎖孔血藍蛋白：

貨號：BXC-BE0090

亞型：大鼠IgG2b，κ

推薦稀釋液：InVivoPure pH 7.0稀釋液

偶聯：未偶聯。提供抗體偶聯服務。

配方：PBS，pH 7.0 不含穩定劑或防腐劑

內毒素：<2EU/毫克（<0.002EU/微克）由LAL凝膠凝固測定法確定

純度：>95% 由SDS-PAGE確定

無菌性：0.2微米過濾

生產：在無動物設施中從細胞培養上清液中純化

純化：蛋白質G

分子量：150 kDa

儲存：抗體溶液應以原始濃度在4°C下儲存。不要冷凍。

InVivoMAb大鼠IgG2b同種型對照文獻參考：

Bauche, D., et al. (2018). "LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis" Immunity 49(2): 342-352 e345.

Triplett, T. A., et al. (2018). "Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme" Nat Biotechnol 36(8): 758-764.

Aloulou, M., et al. (2016). "Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells" Nat Commun 7: 10579.

Finkin, S., et al. (2015). "Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma" Nat Immunol. doi : 10.1038/ni.3290.

Zhang, J., et al. (2015). "Micro-RNA-155-mediated control of heme oxygenase 1 (HO-1) is required for restoring adaptively tolerant CD4+ T-cell function in rodents" Eur J Immunol 45(3): 829-842.